Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if DSGN is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
26 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
136 filers reported a long position in DSGN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | $94.4M | 6.5M | Unchanged |
| Logos Global Management LP | $43.4M | 3M | +53.8% |
| BAKER BROS. ADVISORS LP | $38.8M | 2.7M | +3.6% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $38.5M | 2.7M | +52.5% |
| BlackRock, Inc. | $38.5M | 2.7M | +24.7% |
| Point72 Asset Management, L.P. | $34.2M | 2.4M | -13.1% |
| Trails Edge Capital Partners, LP | $29M | 2M | +134.9% |
| Frazier Life Sciences Management, L.P. | $26.2M | 1.8M | New |
| Vivo Capital, LLC | $23.3M | 1.6M | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.7M | 1.6M | +16.4% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.